The combination of trabectedin (Yondelis; Pharma Mar, Johnson & Johnson) and olaparib (Lynparza; AstraZeneca, Merck) may be a meaningful treatment for certain patients with advanced soft tissue ...

Clinical Trials for Leiomyosarcoma New clinical trials come up depending on what cancer researchers are working on. Some of the current ones for leiomyosarcoma are for a type of treatment called ...

Uterine leiomyosarcoma is a rare and aggressive cancer that occurs in the uterus. Individuals usually require a hysterectomy. Treatments can also include chemotherapy or radiotherapy. Leiomyosarcoma ...

Leiomyosarcoma (LMS) is one of the most common subtypes of soft tissue sarcoma in adults and can occur in almost any part of the body. Uterine leiomyosarcoma is the most common subtype of uterine ...

Uterine leiomyosarcoma is a rare form of cancer. The earlier uterine leiomyosarcoma is diagnosed, the better the outlook. Uterine leiomyosarcoma accounts for 2–5% of all uterine cancers. It starts in ...

Once your treatment is done, your oncologist may tell you that your leiomyosarcoma is in “remission.” This means that signs of your cancer have faded or disappeared. But that doesn’t mean you’re ...

DelveInsight’s, “Leiomyosarcoma Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Leiomyosarcoma pipeline landscape. It covers the Leiomyosarcoma ...

Editor's Note: Uterine leiomyosarcomas are aggressive, heterogeneous cancers associated with high rates of progression and recurrence—and poor outcome. Uterine sarcomas as a group are uncommon cancers ...

Inflammatory leiomyosarcoma, first described by Merchant et al., 1 is a spindle cell tumor of the deep soft tissues that shares morphological features with conventional leiomyosarcoma but that also ...

Soft Tissue and Uterine Leiomyosarcoma The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held ...